Universal 3D printer bioink for Type 1 diabetes cell therapy
Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.
Projectdetails
Introduction
Type 1 Diabetes (T1DM) results from autoimmune destruction of pancreatic insulin-producing β-cells. Nowadays, insulin injections remain the leading therapeutic option. However, injection treatment fails to emulate the highly dynamic insulin release that β-cells provide.
Background
During the last years, 3D cell-laden microspheres have been proposed as a major platform for bioengineering insulin-secreting constructs for tissue graft implantation and as a model for in vitro drug screening platforms.
Current Challenges
Current microsphere fabrication technologies have several drawbacks:
- The need for an oil phase containing surfactants.
- Diameter inconsistency of the microspheres.
- High time-consuming processes, among others.
These technologies have widely used alginate for its rapid gelation, high processability, and low cost. However, its low biocompatible properties do not provide effective cell attachment.
Proposed Solution
To overcome these limitations, Uniink proposes a high-throughput 3D bioprinting methodology that employs an ECM-like microenvironment for effective cell-laden microsphere production. Crosslinking the resulting microspheres with tannic acid (TA) prevents collagenase degradation and enhances spherical structural consistency while allowing the diffusion of nutrients and oxygen.
Customization and Consistency
In addition, the approach allows customization of microsphere diameter with extremely low variability.
Conclusion
In conclusion, we will develop in Uniink a novel bio-printing procedure to fabricate large amounts of reproducible microspheres capable of secreting insulin in response to extracellular glucose stimuli. We expect that Uniink will represent a valid alternative to islet transplantation in T1DM patients, thus bringing cell therapy closer to application in humans.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 30-6-2025 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicineThe SILKink project aims to develop a silk-based bioink for 3D printing bone marrow tissue models to enhance stem cell culture and advance drug development and personalized medicine. | EIC Transition | € 2.494.687 | 2023 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
Beta-cell recovery to counter diabetesDiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine
The SILKink project aims to develop a silk-based bioink for 3D printing bone marrow tissue models to enhance stem cell culture and advance drug development and personalized medicine.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
Beta-cell recovery to counter diabetes
DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.